- Home
- NIE vs CATX Comparison
NIE vs CATX Comparison
Compare NIE & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NIE | CATX |
|---|---|---|
| Founded | 2007 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 704.1M | 569.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | NIE | CATX |
|---|---|---|
| Price | $23.62 | $4.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.11 |
| AVG Volume (30 Days) | 50.9K | ★ 1.4M |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | ★ 9.04% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.71 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.54 | $1.60 |
| 52 Week High | $26.00 | $6.16 |
Technical Indicators
Market Signals| Indicator | NIE | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 30.30 | 43.75 |
| Support Level | $22.74 | $3.24 |
| Resistance Level | $23.81 | $4.54 |
| Average True Range (ATR) | 0.35 | 0.35 |
| MACD | -0.09 | -0.13 |
| Stochastic Oscillator | 18.62 | 24.44 |
Price Performance
Historical ComparisonAbout NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.